Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01627782 · ClinicalTrials.gov registry record · Phase 2

A Study of Ketamine in Patients With Treatment-resistant Depression

A Phase 2 study of Major Depressive Disorder, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 2
Development phase
68
Enrollment target
13
Study locations

NCT01627782 is a Phase 2 study of Major Depressive Disorder that has completed, run by Janssen Research & Development. The registered enrollment target is 68 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (82% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01627782, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 2
Development phase
68 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG Placebo
  • DRUG Ketamine

Study Locations (13)

Connecticut

  • - Hartford
  • - New Haven

Alabama

  • - Birmingham

Arkansas

  • - Little Rock

Colorado

  • - Centennial

Georgia

  • - Atlanta

Maryland

  • - Rockville

New Jersey

  • - Marlton

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2012-08-06
Est. Completion 2013-09-12
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01627782

The ClinicalTrials.gov registry entry for NCT01627782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (82% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01627782 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Connecticut, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT01627782 about?

NCT01627782 is a clinical study titled "A Study of Ketamine in Patients With Treatment-resistant Depression". The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).

What is the current status of trial NCT01627782?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2012-08-06. Estimated completion is 2013-09-12.

What conditions does trial NCT01627782 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT01627782?

The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG).

Who is sponsoring clinical trial NCT01627782?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01627782 being conducted?

This trial has 13 study locations across Alabama, Arkansas, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.